Skip to main content

Early Alzheimer's Disease

Neurology
5
Pipeline Programs
8
Companies
9
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
4
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
1100%
+ 8 programs with unclassified modality

Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.

$26.9B marketMature→ Stable30 products15 companies

Key Trends

  • Extreme market concentration: 68% of spending driven by one FXa inhibitor product
  • Psychiatric and migraine therapies emerging as secondary growth drivers
  • High clinical trial activity (8,279 trials) signals continued pipeline development

Career Verdict

Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISStable
$18.3B
Bristol Myers Squibb·Launch15.0yr
$1.8B
#3BRILINTAStable
$692M
AstraZeneca·Peak10.2yr
#4NUPLAZIDStable
$596M
$530M
Johnson & Johnson·Peak15.6yr

Drug Class Breakdown

FXa Inhibitors (anticoagulant)
$18.3B(68%)

market-defining single product

Dopamine/Serotonin Antagonists (psychiatric)
$2.4B(9%)

stable mature class

P2Y12 Receptor Antagonists (antiplatelet)
$692M(3%)

niche but stable

5-HT2A Inverse Agonists (psychiatric)
$596M(2%)

specialty indication focus

CGRP Receptor Antagonists (migraine)
$931M(3%)

emerging growth segment

Immunomodulators (MS)
$747M(3%)

stable with LOE risk

Other mechanisms
$2.6B(10%)

diverse small products

Career Outlook

Stable

Neurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.

Breaking In

Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.

For Experienced Professionals

Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.

In-Demand Skills

Medical Science Liaisons (MSL) for specialist engagementClinical trial operations expertisePsychiatric/neurodegenerative disease educationRegulatory affairs (given patent cliff activity)Commercial strategy around branded/generic transitions

Best For

Medical Science LiaisonCommercial Brand Manager (anticoagulant/psychiatric franchises)Clinical Operations ManagerRegulatory Affairs SpecialistClinical Development Manager (CGRP/immunomodulator pipelines)

Hiring Landscape

$100K-$199K

Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.

4,186
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

762Growing
434Stable
302Stable

By Department

Commercial(23%)
$169K
Clinical Operations(11%)
$132K
Engineering(8%)
$199K
IT(4%)
$100K
Manufacturing(3%)
$170K

Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Alzheon
AlzheonMA - Framingham
1 program
1
ALZ-801Phase 33 trials
Active Trials
NCT06304883Active Not Recruiting163Est. Jan 2027
NCT04770220Completed325Est. Jul 2024
NCT04693520Completed84Est. Jul 2025
Nia Therapeutics
Nia TherapeuticsMA - Boston
1 program
1
CT1812Phase 2
Cognition Therapeutics
Cognition TherapeuticsPA - Pittsburgh
1 program
1
CT1812Phase 21 trial
Active Trials
NCT05531656Active Not Recruiting540Est. Apr 2027
MSD
MSDIreland - Ballydine
1 program
1
MK-2214Phase 21 trial
Active Trials
NCT07033494Recruiting340Est. Apr 2029
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
MK-2214Phase 2
Eisai
EisaiChina - Liaoning
2 programs
E2609PHASE_11 trial
Lecanemab IVPHASE_31 trial
Active Trials
NCT02859207Completed32Est. Jan 2017
NCT03887455Active Not Recruiting1,906Est. Jun 2029
NewAmsterdam Pharma
NewAmsterdam PharmaNARRDEN, Netherlands
1 program
ObicetrapibPHASE_21 trial
Active Trials
NCT05161715Completed13Est. Jun 2023
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
SemagludtidePHASE_3Peptide1 trial
Active Trials
NCT04777396Completed1,840Est. Jan 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
AlzheonALZ-801
AlzheonALZ-801
Novo NordiskSemagludtide
EisaiLecanemab IV
MSDMK-2214
Cognition TherapeuticsCT1812
NewAmsterdam PharmaObicetrapib
AlzheonALZ-801
EisaiE2609

Clinical Trials (9)

Total enrollment: 5,243 patients across 9 trials

Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Start: Apr 2024Est. completion: Jan 2027163 patients
Phase 3Active Not Recruiting

An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

Start: May 2021Est. completion: Jul 2024325 patients
Phase 3Completed

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

Start: May 2021Est. completion: Jan 20261,840 patients
Phase 3Completed
NCT03887455EisaiLecanemab IV

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

Start: Mar 2019Est. completion: Jun 20291,906 patients
Phase 3Active Not Recruiting

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Start: Jul 2025Est. completion: Apr 2029340 patients
Phase 2Recruiting

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

Start: Jun 2023Est. completion: Apr 2027540 patients
Phase 2Active Not Recruiting

Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease

Start: Jan 2022Est. completion: Jun 202313 patients
Phase 2Completed

Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease

Start: Sep 2020Est. completion: Jul 202584 patients
Phase 2Completed

A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects

Start: Aug 2016Est. completion: Jan 201732 patients
Phase 1Completed

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 5,243 patients
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.